Exelixis (EXEL) traded down -1.19 % during a 24 hours period ending at 08:03 PM Central Europe on Monday 26th. One Exelixis stock can currently be bought for about USD 64.89 on popular exchanges. Current supply of Exelixis stocks is 247.8 mn. Exelixis has a current market capitalization of USD 16 bn and approximately USD 133.3 mn worth of Exelixis was traded on exchanges in the last 24 hours. Since last month end, Exelixis has traded 11.35 % up. Simple moving average of last 200 days is at USD 50.36. The highest price of past 52 weeks was recorded at USD 65.5 on 10/22/2026. 52 weeks low was at USD 36 on 11/03/2025.
Here is how related stocks have performed in the past 24 hours:
Dynatrace (DT) traded up 1.07 % and now trades at USD 64.51. Dynatrace has a market capitalisation of USD 18.5 bn. Current price/earnings ratio for Dynatrace is 127.07.
Plains All Amer Pipeline (PAA) traded up 2.82 % and now trades at USD 26.83. Plains All Amer Pipeline has a market capitalisation of USD 18.8 bn. Plains All Amer Pipeline has a current price to earnings ratio of 22.96.
Sofi (SOFI) traded down -1.05 % and now trades at USD 14.46. Current market capitalisation for Sofi is USD 18.9 bn. Current price/earnings ratio for Sofi is 30.74. SoFi Technologies Inc. is scheduled to disclose its latest quarterly results on October 27, following the quarter that ended September 30. Analysts anticipate the company to report a modest increase in earnings per share compared to the same period last year, though the increase is expected to be small. Revenue expectations for the quarter show a slight decline relative to the previous year, with analysts projecting a modest drop in sales figures. For the current fiscal year, expectations point to a higher earnings per share than last year’s figures, and revenue outlooks for the year indicate a moderate rise compared with the prior year. The company’s upcoming announcement will confirm whether these projections are met and provide further detail on its performance and guidance for the remainder of the fiscal year.
Zimmer Biomet (ZBH) traded down -0.25 % and now trades at USD 96.78. Current market capitalisation for Zimmer Biomet is USD 18.8 bn. Current price/earnings ratio for Zimmer Biomet is 23.97.
Medpace (MEDP) traded up 2.33 % and now trades at USD 671.16. Current market capitalisation for Medpace is USD 18.7 bn. Medpace has a current price to earnings ratio of 36.95.
About Exelixis
Exelixis, Inc. is a development-stage biotechnology company that specializes in discovering and developing small-molecule therapeutics for treating cancer and other serious diseases. The company offers medications to treat kidney and thyroid cancer as well as advanced melanoma. Exelixis forms strategic alliances with pharmaceutical and biotechnology companies and trades on the Nasdaq stock exchange.
